Drug Trial Radar · NCT03939312
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
Last checked: Nov 20, 2026Latest source record: May 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
685
Actual
Start
May 6, 2019
Primary completion
Mar 31, 2021
Study completion Mar 31, 2021
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Conditions
- Episodic Migraine
Interventions
AtogepantDrug
Atogepant Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)Time frame: From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44)
Locations
113 sites in 1 country. Site status is shown where the registry gives one.
Synexus Clinical Research US, Inc.
Chandler, Arizona
Alea Research
Phoenix, Arizona
Central Phoenix Medical Clinic
Phoenix, Arizona
Orange Grove Family Practice
Tucson, Arizona
Principals Research Group
Hot Springs, Arkansas
Arkansas Clinical Research
Little Rock, Arkansas
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Med Center Medical Clinic
Carmichael, California
Neuro Pain Medical Center
Fresno, California
California Headache and Balance Center
Fresno, California
Grossmont Center for Clinical Research
La Mesa, California
Paradigm Clinical Research Centers, Inc
La Mesa, California
Torrance Clinical Research Institute, Inc.
Lomita, California
Long Beach Clinical Trials Services
Long Beach, California
Pharmacology Research Institute
Newport Beach, California
Newport Beach Clinical Research Associates
Newport Beach, California
Excell Research, Inc.
Oceanside, California
Rancho Cucamonga Clinical Trials
Rancho Cucamonga, California
Desert Valley Research
Redlands, California
George J. Rederich, M.D. Inc.
Redondo Beach, California
Optimus Medical Group
San Francisco, California
California Neuroscience Research
Sherman Oaks, California
Alpine Clinical Research Center
Boulder, Colorado
Colorado Springs Neurological Associates
Colorado Springs, Colorado
Colorado Neurological Institute
Englewood, Colorado
New England Institute for Clinical Research
Stamford, Connecticut
Aventura Neurological Associates
Aventura, Florida
Neurology Offices of South Florida
Boca Raton, Florida
Sarkis Clinical Trials- Gainesville
Gainesville, Florida
Westside Center for Clinical Research
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Well Pharma Medical Research, Corp
Miami, Florida
Clinical Neuroscience Solutions
Orlando, Florida
Neurology Associates of Ormond Beach
Ormond Beach, Florida
Sarasota Memorial Hospital Clinical Research Center
Sarasota, Florida
Meridien Research
St. Petersburg, Florida
Axiom Clinical Research of Florida
Tampa, Florida
University of South Florida
Tampa, Florida
Neurotrials Research
Atlanta, Georgia
Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology
Atlanta, Georgia
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.